Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension

Pulmonary Circulation

Volumn 3, Issue 1, 2013, Pages 116-120

  Raina, Amresh ^a   Coons, James C ^a   Kanwar, Manreet ^a   Murali, Srinivas ^a   Sokos, George ^a   Benza, Raymond L ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Case study; Prostacyclin; Prostanoid; Pulmonary arterial hypertension; Transition; Treprostinil

Indexed keywords

EID: 84899628597     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.109926     Document Type: Article

References (19)

1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65.
2. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc. and the Pulmonary Hypertension Association. Circulation 2009;119:2250-94.
3. Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006;28:1195-203.
4. Hiremath J, Thanikachalam S, Parikh K, Shanmugasundaram S, Bangera S, Shapiro L, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial. J Heart Lung Transplant 2010; 29:137-49.
5. Lang I, Gomez-Sanchez M, Kneussl M, Naeije R, Escribano P, Skoro-Sajer N, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006;129:1636-43.
6. Tapson VF, Gomberg-Maitland M, McLaughlin VV, Benza RL, Widlitz AC, Krichman A, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: A prospective, multicenter, open-label, 12-week trial. Chest 2006;129:683-8.
7. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
8. Kallen AJ, Lederman E, Balaji A, Trevino I, Petersen EE, Shoulson R, et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol 2008;29:342-9.
9. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915-22.
10. Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004;44:209-14.
11. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
12. de Jesus Perez VA, Rosenzweig E, Rubin LJ, Poch D, Bajwa A, Park M, et al. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol 2012;110:1546-50.
13. Nelsen AC, Laliberte KJ, Zaccardelli DS, Gotzkowsky SK. Pharmacokinetics of inhaled treprostinil sodium in healthy volunteers. Am J Respir Crit Care Med 2010;181:A3348.
14. Voswinckel R, Enke B, Reichenberger F, Kohstall M, Kreckel A, Krick S, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: Results from randomized controlled pilot studies. J Am Coll Cardiol 2006;48:1672-81.
15. Wade M, Baker FJ, Roscigno R, DellaMaestra W, Hunt TL, Lai AA. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. J Clin Pharmacol 2004;44:83-8.
16. Wade M, Baker FJ, Roscigno R, DellaMaestra W, Hunt TL, Lai AA. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. J Clin Pharmacol 2004; 44:503-9.
17. McSwain CS, Benza R, Shapiro S, Hill N, Schilz R, Elliott CG, et al. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. J Clin Pharmacol 2008;48:19-25.
18. Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, et al. The REVEAL Registry riskscore calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 2012;141:354-62.
19. Steiner MK, Preston IR, Klinger JR, Criner GJ, Waxman AB, Farber HW, et al. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: A pilot study. Chest 2006;130:1471-80.